As in case of tumor heterogeneity, by combining nanobodies with low affinity for two targets that are co-expressed by tumor cells but not by NK or T cells, e.g. CD38 and BCMA, it might be possible to specifically deplete only cells expressing both target antigens and thus to develop nanobody-based antibody constructs with lower off-target effects. The gene discussed is TNFRSF17; the disease is neoplasm.